Lawrence Green, MD
Procedural Dermatology · Rockville, MDNPI 1073581344
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $775,221 of the $1,075,300 with a category attached, or 72.1%. It is spread thinly across 40 manufacturers, the largest accounting for just 11.9%. Reporting peaked in 2019 at $334,931 and has fallen 77.3% since, to $76,062 in 2025.
Across 1,410 payments — averaging $762.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$128K
- E.r. Squibb & Sons, L.L.C.$99K
- UCB, Inc.$98K
- Incyte Corporation$92K
- Sun Pharmaceutical Industries Inc.$89K
- Bristol Myers Squibb$78K
- plus $491K from 34 others
Across 571 payments — averaging $4936.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$711K
- Takeda Pharmaceuticals U.S.A., Inc.$493K
- Janssen Research & Development, LLC$321K
- Bristol Myers Squibb$310K
- Amgen$187K
- Pfizer$148K
- plus $648K from 9 others
What the payments were for
- Consulting fees$169,69316%
- Speaking & faculty fees$775,22172%
- Travel & lodging$90,6438%
- Food & beverage$39,5534%
- Education$730%
- Gifts$1170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few procedural dermatology providers in Marylandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clindamycin Phosphate | 13 | $2,208 |
| Gentamicin Sulfate | 12 | $394 |
| Triamcinolone Acetonide | 32 | $134 |
Paid to pharmacies, not to this prescriber.
Other procedural dermatology in Rockville
- Sharleen St Surin-LordLargo$219K
- Joseph LeeBethesda$13K
- Sarika SnellChevy Chase$13K
- Amanda PittilloTimonium$7K
- Diane FordFrederick$2K
- Geeta ShahChevy Chase$2K
- Tania PetersChevy Chase$2K
- Tina WestChevy Chase$1K
- Mariusz WojnarskiFort Meade$1K
- Thomas SmithBaltimore$442
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.